HomeCompareTMOAY vs PFE

TMOAY vs PFE: Dividend Comparison 2026

TMOAY yields 74.07% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TMOAY wins by $1.22M in total portfolio value
10 years
TMOAY
TMOAY
● Live price
74.07%
Share price
$2.70
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.27M
Annual income
$347,213.33
Full TMOAY calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — TMOAY vs PFE

📍 TMOAY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTMOAYPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TMOAY + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TMOAY pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TMOAY
Annual income on $10K today (after 15% tax)
$6,296.30/yr
After 10yr DRIP, annual income (after tax)
$295,131.33/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, TMOAY beats the other by $272,811.43/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TMOAY + PFE for your $10,000?

TMOAY: 50%PFE: 50%
100% PFE50/50100% TMOAY
Portfolio after 10yr
$659.4K
Annual income
$186,736.02/yr
Blended yield
28.32%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

TMOAY
No analyst data
Altman Z
2.3
Piotroski
3/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TMOAY buys
0
PFE buys
0
No recent congressional trades found for TMOAY or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTMOAYPFE
Forward yield74.07%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$1.27M$49.6K
Annual income after 10y$347,213.33$26,258.71
Total dividends collected$1.09M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: TMOAY vs PFE ($10,000, DRIP)

YearTMOAY PortfolioTMOAY Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$18,107$7,407.41$9,153$693.39+$9.0KTMOAY
2$31,910$12,535.42$8,593$849.25+$23.3KTMOAY
3$54,790$20,645.72$8,336$1,066.78+$46.5KTMOAY
4$91,755$33,129.47$8,437$1,384.80+$83.3KTMOAY
5$150,029$51,851.19$9,013$1,875.40+$141.0KTMOAY
6$239,766$79,235.77$10,306$2,680.72+$229.5KTMOAY
7$374,895$118,345.50$12,820$4,101.38+$362.1KTMOAY
8$574,076$172,937.82$17,673$6,826.70+$556.4KTMOAY
9$861,756$247,494.40$27,543$12,591.86+$834.2KTMOAY
10$1,269,292$347,213.33$49,560$26,258.71+$1.22MTMOAY

TMOAY vs PFE: Complete Analysis 2026

TMOAYStock

TomTom N.V. develops and sells navigation and location-based products and services worldwide. The company operates in two segments, Location Technology and Consumer. It offers standard definition, advanced driver assistance system (ADAS), high definition (HD) maps, and map data, as well as places for map products; traffic and travel information products, including real-time traffic, hazard warning, speed camera, speed profile, road analytics, fuel and weather services, electric vehicle (EV) and parking services, and routing; and navigation products, such as navigation engine, traffic and travel information, navigation user interface, EV routing and range, and maps for automotive. The company also provides AutoStream, a solution that enables fast and efficient map delivery of the TomTom automated driving (AD) and ADAS Maps; RoadCheck, a tool for carmakers to determine when, where, and under what conditions their vehicles can safely activate AD functions; TomTom indigo, a digital cockpit platform; and virtual horizon products. In addition, it offers road analytics solutions, including traffic stats, origin destination analysis, route monitoring, road event reporter, and junction analytics; and shop products, such as navigation devices, accessories, and map updates, as well as support services. The company serves the automotive, fleet management and logistics, mobility and on-demand, road traffic management, and location intelligence industries. TomTom N.V. was founded in 1991 and is headquartered in Amsterdam, the Netherlands.

Full TMOAY Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this TMOAY vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TMOAY vs SCHDTMOAY vs JEPITMOAY vs OTMOAY vs KOTMOAY vs MAINTMOAY vs JNJTMOAY vs MRKTMOAY vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.